Cao Ya-di, Gong Rui-Juan, Chen Ning, Liu Wei
School of Management,Beijing University of Traditional Chinese Medicine Beijing 100029,China.
Zhongguo Zhong Yao Za Zhi. 2019 Mar;44(6):1284-1288. doi: 10.19540/j.cnki.cjcmm.2019.0024.
In recent years,the number of patent applications for traditional Chinese medicine( TCM) inventions has increased rapidly,but the authorization rate has declined. Listed TCM enterprises are a group of active innovators in this field,so this paper analyzes their patent quality by combining patent application and authorization with R&D investment of enterprises in order to explore a practical way to improve the quality of TCM patents. The conclusions are as follows: the R&D investment of listed TCM enterprises is insufficient and the gap between enterprises is large; the number of patent applications is within a reasonable range,but some enterprises still have abnormal patent applications,and patent quality needs to be improved; in addition,the patent operation capacity of enterprises still needs to be improved. In this phenomenon,enterprises should improve R&D investment,strengthen the level of technological innovation,improve the ability of patent operation,and consciously eliminate the output of " abnormal patents"; the patent administrative department should optimize policy direction which is beneficial to the improvement of patent quality,grasp the normal and reasonable examination scale,and jointly improve the quality of TCM patents.
近年来,中药发明的专利申请数量增长迅速,但授权率却有所下降。上市中药企业是该领域的一群活跃创新者,因此本文通过将专利申请与授权情况和企业研发投入相结合来分析其专利质量,以探索提高中药专利质量的切实可行途径。研究结论如下:上市中药企业研发投入不足,企业间差距较大;专利申请数量在合理范围内,但部分企业仍存在异常专利申请,专利质量有待提高;此外,企业的专利运营能力仍需提升。针对这一现象,企业应加大研发投入,加强技术创新水平,提高专利运营能力,自觉杜绝“异常专利”的产出;专利管理部门应优化有利于提高专利质量的政策导向,把握正常合理的审查尺度,共同提高中药专利质量。